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Abstract We report the expression in E. coli of a proinsulin 
fusion protein carrying a modified interleukin-2 N-terminal pep- 
tide linked to the N-terminus of proinsulin by a lysine residue. The 
key aspects investigated were: (a) the expression of the fused 
IL2-PI gene, (b) the folding efficiency of the insulin precursor 
when still carrying the N-fused peptide and (c) the selectivity of 
the enzymatic leavage reaction with trypsin in order to remove 
simultaneously the C-peptide and the N-terminal extension. It 
was found that this construction expresses the chimeric proinsufin 
at high level (20%) as inclusion bodies; the fused protein was 
refolded at 100-200/xg/ml to yield about 80% of correctly folded 
proinsulin and then it was converted into insulin by prolonged 
reaction (5 h) with trypsin and carboxypeptidase B at a low 
enzymelsubstrate rate (I :600). This approach is based on a single 
enzymatic reaction for the removal of both the N-terminal fused 
peptide and the C-peptide and avoids the use of toxic cyanogen 
bromide. 
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1. Introduction 
Human insulin was the first recombinant protein expressed 
in bacteria to be produced at industrial scale, more than 10 
years ago [1]. As early attempts to obtain recombinant insulin 
by the expression of the proinsulin gene (coding for the se- 
quence B-chain-C-peptide-A chain) in bacteria failed due to the 
rapid intracellular degradation of the protein, insulin was at- 
tained as a fusion or chimeric protein, carrying at its N-termi- 
nus a polypeptide resistant o intracellular degradation [1-3]. 
This sequence is linked to the B-chain N-terminus by a 
methione residue. For these constructions, removal of the N- 
terminal fused peptide is accomplished at an early stage in the 
process by chemical cleavage with cyanogen bromide at the 
methionine r sidue [1]. This approach requires two independent 
cleavage reactions: firstly, prior to folding, for removing the 
fused peptide, and then, after folding, for removing the C- 
peptide. 
Due to the increasing demand of human insulin [4] and the 
complexity of handling large amounts of cyanogen bromide at 
the industry, the search for a process that could avoid the use 
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of this highly toxic product has been under research. Recently, 
two alternative approaches are described. One consists of the 
biosynthesis of an inverted proinsulin molecule, A-C-B, and its 
conversion into human insulin by enzymatic leavage of the 
C-peptide [5,6]. In contrast o the 'normal'  proinsulin, the in- 
verted proinsulin is stable. A second approach is based on the 
selective removal of a short N-terminal extension from a previ- 
ously folded insulin precursor by the action of dipeptidyl amino 
peptidase-1 [7]. 
We explore here a different approach. A fused proinsulin 
precursor (IL2-PI) is constructed that bears a tryptic site (ly- 
sine) at the end of the N-fused peptide, instead of the traditional 
methionine residue. Folding is accomplished at the stage of the 
chimeric proinsulin molecule and then both the N-fused se- 
quence and the C-peptide are removed simultaneously, in a 
single step, by reaction with trypsin. As fused peptide, a modi- 
fied N-terminal region of human interleukin-2 (residues 1 to 
22), followed by an hexapeptide, was designed (Fig. 1). A re- 
lated sequence yielded high expression levels when fused to the 
antigenic determinants of HIV-I proteins in E. coli [8]. It was 
found that the IL2-PI construction expresses the chimeric pro- 
insulin at high level (20%) as inclusion bodies; this fused protein 
was folded at low protein concentration (100 200 #g/ml) to 
yield about 80% of correctly folded proinsulin and then it was 
converted into insulin by prolonged reaction (5 h) with trypsin 
and carboxypeptidase B at a low enzyme/substrate rate (1 : 600). 
2. Materials and methods 
Synthetic oligonucleotides and restriction enzymes were supplied by 
HeberBiotec (Cuba). The proinsulin gene was synthesized by Jimenez 
et al. [9]. Sequence grade proteinases were from Boehringer Mannheim 
(Germany); all other reagents were analytical grade from commercial 
suppliers. 
2.1. Plasmid construction and cell culture 
The prototrophic E. coli K12 strain W3110 (F-) was transformed 
according to the method of Hanahan [10] with plasmid plSL-31. This 
is a vector derived from plasmid pBR322, coding for the N-terminal 
sequence of interleukin-2 (residues 1 to 22) in which lysine residues 8 
and 9 in the IL-2 sequence have been replaced by alanine and glutamine, 
respectively, followed by a pentapeptide, a lysine residue and the proin- 
sulin (PI) sequence (Fig. 1). The expression was regulated by the trp 
promoter. The recombinant strain was grown overnight in Luria Ber- 
tani medium in the presence of tryptophan (100 #g/ml). Then, 500 ml 
of culture were inoculated into 5 1 fermentation medium, containing 1% 
M9 salts, 2% casein hydrolysate, 0.4% glucose, 1% tryptone and 50 
#g/ml ampicillin and grown under aeration at 37°C. After 12 h, the cells 
were harvested and kept at -70°C until use. 
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2.2. Isolation and purification of IL2-PI 
All procedures were done at 0-4°C. Centrifugations were done at 
3,000 rpm for 20 rain. Twenty grams of harvested cells were homoge- 
nated in 100 ml of the standard buffer (20 mM Tris-HCl pH 8.0, I mM 
EDTA, 0.1 rnM phenylmethanesulfonyl fluoride), supplemented with 
I M urea and 1% Triton X-100 and disrupted by sonic oscillation (3 
cycles, 3 min each). After centrifugation, the sediment was resuspended, 
agitated and centrifuged successively in 25 ml of the standard buffer 
supplemented with 4 M urea and 2% Triton X-100, and then twice in 
25 ml of the standard buffer. The sediment was solubilized with 12 ml 
of the standard buffer supplemented with 8 M urea (pH 8.9), stirred for 
30 min and centrifuged, The supernatant was diluted with the same 
buffer to a final concentration f about 3 mg/ml. Cysteine groups were 
converted into their S-sulfonates by oxidative sulfitolysis, accomplished 
by the addition of sodium sulfite and sodium tetrathionate (20 eq. 
sulfite/10eq, tetrathionate/1 eq.cysteine). After 6 h, the reaction was 
stopped by dilution with water to a final urea concentration f 2 M, 
and by acidification at pH 4.0 with 2 N HCI. The IL2-PI S-hexasulfon- 
ate was collected as an abundant white precipitate, which was washed 
twice with 0.01% HC1 and kept at -20°C or alternatively, it was imme- 
diately purified by anion exchange chromatography on a Q-Sepharose 
Fast Flow column (Pharmacia, Sweden). The column was equilibrated 
in the loading buffer (8 M urea, 20 mM Tris, 0.2 M NaC1, pH 8.9), the 
fusion protein hexasulfonate was dissolved and loaded at a protein 
concentration f about 3 mg/ml and the column was eluted with an 
increasing NaCI gradient. IL2-PI S-hexasulfonate eluted at about 
a 
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HAPTSSSTAQTQLQLEHLLLDLQ I FLDTK 
Fig. 1. (a) The chimeric IL2-PI sequence: a N-terminal fused peptide 
containing residues 1to 22 of human interleukin-2, in which Lys 8 and 
Lys 9 have been replaced by Ala and Gln respectively, followed by an 
hexapeptide (QIFLDTK), the insulin B-chain (Phe ~ to Thr3°), the pro- 
insulin C-peptide and the insulin A-chain (Gly ~ toAsn 2~). The additional 
methionine incorporated at the N-terminus of the IL-2 sequence is
partially removed uring biosynthesis. (Molecular mass: 12732,2 Da, 
insulin represents 46% of the molecular mass for the fusion protein.) 
(b) Genetic onstruction on plasmid pISL-31. 
0.6 M NaC1 and then precipitated by dilution of urea to a final concen- 
tration of 2 M after acidification at pH 4.0. 
2.3. Folding of the fusion protein and its enzymatic conversion i to insulin 
IL2-PI S-hexasulfonate was dissolved in the folding buffer (50 mM 
glycine, 1 mM EDTA, pH 10.5) and the solution was degassed. In order 
to exchange the sulfonate groups and to induce disulfide bond forma- 
tion, fl-mercaptoethanol was added (1.5 eq. per eq. of S-sulfonate) [1]. 
Folding was performed at protein concentrations varying from 25 pg/ 
ml to 1 mg/ml, at 4°C for varied times from 2 h to 24 h. To stop the 
reaction, the pH was adjusted to 4.0. Folding products were isolated 
by reversed phase HPLC, lyophilized, dissolved in 200 mM Tris, pH 
9.0, to a protein concentration f 1 mg/ml and digested with trypsin 
(E/S: 1:600, w/w) or trypsin plus carboxypeptidase B (E/S: 1:600) at 
37°C for 5 h. In order to confirm the structure of the main product, 
the peak corresponding to human insulin as well as a human insulin 
standard were cleaved with GIu-C endoproteinase at 25°C for 5 h (E/S: 
1:20, w/w; in 0.2 M Tris, pH 8.0) and the digestion products were 
isolated by reversed phase HPLC and analyzed by fast atom bombard- 
ment mass spectrometry (FAB-MS). 
2.4. Ultrastructural studies 
The sample consisting of pelleted cells (2 × 107 cell) from transformed 
W3110 E. coli was fixed with 3.2% glutaraldehyde, and post-fixed for 
1 h in 1% OsO4. Then, it was rinsed with 0.1 M PBS, pH 7.2, and 
deshydrated in increasing ethanol concentrations. The embedding was 
in Spurr. The blocks were sectioned with an ultramicrotome (LKB 
2188) and the ultrathin sections were placed on 400 mesh grids without 
membrane. All sections were examined ina Jeol-JEM 2000 EX electron 
microscope. 
2.5. Fast atom bombardment mass spectroscopy 
Mass spectra were recorded on a JEOL JMS-HX 110 mass pectrom- 
eter equipped with a standard FAB ion source using a xenon ionizing 
beam (4 kV). Mixtures of glycerol and thioglyeerol (1: 1) and dithio- 
threitol and dithioerythritol (5: 1) were used as matrix. The ion source 
was fixed at 10 kV accelerating potential and data acquired with a 
JEOL JMA-DA5000 mass data analysis ystem. 
2.6. Other analytical procedures 
Sodium dodecyl sulfate polyacrylamide lectrophoresis (SDS- 
PAGE) was performed on a 15% acrylamide gel according to Laemmli 
[11]. Sulfitolysis reactions were analyzed by PAGE in 8 M Urea on 7.5% 
polyacrylamide g ls without SDS. Proteins were visualized by Coomas- 
sie blue staining. Protein recoveries were calculated on a weight basis, 
as determined by the Bradford method. Reversed phase HPLC was 
accomplished with dual wavelength at 214 nm and 280 nm with auto- 
matic data processing by using a Vydac C-4 column for protein analysis 
and a Vydac C-18 column (250 × 4.6 ram) for peptide mapping. Sol- 
vents and gradients were: for peptide mapping: A: 0.1% aqueous TFA, 
B: 0.1% TFA in acetonitrile (0% B to 60% B in 120 min); for sulfonated 
IL2-PI, A: 0.1% sodium phosphate, pH 7.0, B: 40% (A) + 60% acetoni- 
trile (25% B to 65% B in 40 min); for folding products, A: 72% 0.15 M 
ammonium sulfate pH 4.0 + 28% acetonitrile, B: 40% 0.15 M ammo- 
nium sulfate pH 4.0 + 60% acetonitrile (10% B to 45% B in 10 min and 
then to 100% B in 55 rain). 
3. Results and discussion 
A major problem in the production of human proinsulin in 
E. coli is its intracellular degradation. In order to achieve pro- 
tein stability, PI has been expressed as a fusion protein which 
is resistant to proteolysis, the N-terminal extension being artifi- 
cially engineered or selected from bacterial proteins [1-3]. 
A system for the overexpression f  heterologous proteins in 
E. coli was recently developed, based on the fusion of the 
N-terminus (residues 1to 62) of human interleukin-2 to several 
target proteins. This system allowed high expression (20% to 
30%) of the immunodominant regions of HIV-1 and HIV-2 
proteins [8]. In a previous design, we fused the PI gene to the 
IL-2 (1 62) sequence. This construction yielded about 30% of 
L.R. Castellanos-Serra et al./FEBS Letters 378 (1996) 171-176 173 
~i ¸
Fig. 2. Microphotograph s owing at ultrastructural level the presence 
of an inclusion body (IB) inside the E. coli transformed cell, corre- 
sponding to the IL-2PI protein. 
the chimeric protein but resulted in a very low solubility that 
difficulted further purification and folding (unpublished re- 
sults). Therefore, a shorter fusion sequence was then designed, 
corresponding to a modified IL2 N-terminal region (1 to 22) 
in which two lysine residues were mutated to suppress these 
additional tryptic sites. In order to introduce a tryptic cleavage 
site at the end of the fused sequence, a hexapeptide containing 
lysine at its C-terminus was linked to the N-terminus of B-chain 
in the PI sequence (Fig. 1). 
3. l. Expression and isolation of  IL-2PI  as inclusion bodies 
The transformed strain E. coli W3110 containing plasmid 
pISL-31 was able to express the fusion protein IL2-PI as was 
evidenced by SDS-PAGE, densitometry and Western blot of 
disrupted cell extracts. The expressed protein accumulated at
the cytosol in morphological distinct inclusion bodies identified 
by electron microscopy, and represented about 20% of the total 
cellular protein (Fig. 2). 
Different concentrations of urea (from 2 M to 8 M) in Tris- 
EDTA buffer were evaluated for the selective xtraction of 
E. coli contaminants from the insoluble protein fraction. It was 
concluded that one extraction with 4 M urea during 3 h sub- 
Table 1 
Molecular ions of peptide fragments corresponding to the enzymatic 
digestion of folding products 1 and 2 (Fig. 4) 
Peak Mass + H ÷ (AMU) Assignment 
l 859.0 B-chain (23 29) 
2 3148.5 C-peptide 
3 4865.2 des-octa-insulin 
4 5808.7 insulin 
5 3112.1 N-extension 
6 3243.3 N-extension +Met 
7 2380.2 A-chain oxidized 
8 2485.9 B-chain (1-22) oxidized 
stantially eliminated most of the contaminants, he pellet was 
enriched in IL2-PI up to about 80% (Fig. 3), while no looses 
of IL2-PI in the supernatant were observed by electrophoresis. 
According to this, 200 mg of IL2-PI were obtained from 20 g 
wet weight cells. After purification by reversed phase chroma- 
tography, the primary structure of the fusion protein was veri- 
fied by peptide mapping, FAB MS and automatic sequencing. 
3.2. Oxidative sulfitolysis and purification of  IL2-PI  
hexasulJonate 
An efficient procedure for renaturing recombinant proin- 
sulin was first developed by Frank and co-workers [1]; this 
procedure consists of (a) removal of the fused N-terminal se- 
quence from the chimeric protein by cleavage with cyanogen 
bromide, (b) conversion of PI into its S-hexasulfonate, which 
is purified at this stage by anion exchange chromatography and 
(c) single step non-oxidative transformation f PI-S-sulfonate 
at basic pH into renatured proinsulin presenting its three disul- 
fide bridges correctly arranged. In the present approach, a key 
point is the simultaneous removal on the fused sequence and 
the C-peptide in a single step after protein renaturation, there- 
fore sulfitolysis was accomplished at the stage of the fused 
precursor. In order to establish optimal reaction conditions, 
oxidative sulfitolysis of IL2-PI was carried out at variable 
molar ratios for sodium sulfite/Cys-SH groups (from 1/1 to 
50/1), with a constant proportion between sulfite and 
tetrathionate equal to 1/0.5. It was observed that conversion of 
IL2-PI into its hexasulfonate was complete in 1 h at room 
temperature, at a sulfite to cysteine molar ratio of 20/1. The 
fusion protein S-hexasulfonate was purified by anion exchange 
chromatography. The loading capacity of the matrix was about 
50 mg of total protein per ml of gel. Equilibration of the matrix 
in 8 M urea was essential for the efficient retention of the 
protein during loading. The non-retained fraction contained 
only contaminant proteins while IL2-PI hexasulfonate eluted 
by increasing NaC1 concentration as a highly pure fraction 
(over 98% as evaluated by reversed phase HPLC at neutral pH 
and 8 M urea PAGE). 
a b c d e f g 
,IP 
Fig. 3. SDS-15% polyacrylamide g l electrophoresis of [L2-PI fusion 
protein. (a,b) The initial crude xtract of E. coli proteins containing the 
overexpressed (about 20%) fusion protein IL2-PI; (c,d) the inclusion 
bodies were extracted with (c) 2 M or (d) 4 M urea in Tris buffer. After 
selective xtraction at 4 M urea, the protein was recovered with rela- 
tively high purity (approximately 80%); (e,f) the folded IL2-PI, isolated 
by reversed phase HPLC (corresponds to fraction 1, Fig. 4a); (g) molec- 
ular weight markers, the including cytochrome c (lower band). 
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Fig. 4. Folding of the fusion protein IL2-PI. (a) HPLC of the folding reaction after 6 h. (Protein concentration: 100/~g/ml.) (b  Peptide map of fraction 
1 in Fig. 4a, digested with trypsin and carboxypeptidase B. (c) Tryptic map of fraction 2 in Fig. 4a. The molecular ions of peptides are shown in 
Table 1. 
3.3. Folding of the IL2-Pl fusion protein 
The conversion of the S-hexasulfonate into the renatured 
fusion protein was done according to the procedure previously 
reported for PI [1], which is based on the sulfonate xchange 
reaction with a thiol reagent. Analysis of the folding process by 
reversed phase HPLC with water/acetonitrile/TFA as solvents, 
resulted in poor resolution but was highly improved by using 
a gradient of acetonitrile in aqueous ammonium sulfate at pH 
4.0. 
Two main fractions were resolved (Fig. 4a) in a relative 
proportion of 80:20, as determined by protein quantitation 
after HPLC separation. Fraction 1 was digested with trypsin 
and carboxypeptidase B (Fig. 4b). Mass values of the peptides 
are presented inTable 1 and corresponded to insulin, C-peptide 
and two peaks (5 and 6, Fig 4b) at higher etention time, from 
the fused IL-2 peptide, differing by a methionine r sidue at their 
NH2-terminus (generated by partial intracellular p ocessing of 
the N-terminal residue in bacteria). Two minor components (1 
and 3, Fig. 4b) were generated by internal cleavage at Arg 22 
(B-chain). Thus, the major compound, with lower retention 
time on HPLC corresponded to the fusion protein with the 
correctly folded PI domain. 
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Fig. 5. Effect of protein concentration the folding reaction. Folding 
concentrations are: (a) 200/lg/ml; (b) 400/lg/ml; (c) 600 Hg/ml; (d) 800 
/lg/ml. In all cases the injected amount corresponded to the soluble 
fraction after centrifugation of 100/lg protein. 
The analysis of tryptic peptides from the minor product 
(fraction 2, Fig. 4a) indicated the absence of interchain disulfide 
bridges (Fig. 4c and Table 1); peak 7 corresponded by its mass 
values to A-chain presenting two intramolecular disulfide 
bridges, while peak 8 corresponded to the Phe l -Ar f  2 (B-chain) 
fragment with one disulfide bridge. The minor folding product 
corresponds then to a misfolded PI domain, in which inter- 
chain disulfide bridges are absent and replaced by intra-chain 
bridges. The amino acid composition of all tryptic peptides, 
derived from fraction 1 and fraction 2 was determined and 
confirmed the assignments made by FAB-MS. 
Reaction time was not critical on the yield of folded IL2-PI. 
After 6 h at 4°C the reaction showed steady ields as observed 
by the HPLC profile when it was monitored uring 24 h; fur- 
ther experiments were evaluated after 6 h of reaction. A very 
critical factor in the efficiency of the folding reaction was IL-PI 
S-sulfonate concentration. When this parameter was varied 
from 25 ¢tg/ml to 1 mg/ml, it was found that, as protein concen- 
tration increased, folding yields decreased dramatically (Fig. 5). 
Thus, at a concentration of 800/~g/ml, the yield of renatured 
IL2-PI was only 15% referred to the yield at 200 Hg/ml. At the 
same time, the relative proportion of fractions 1 to 2 decreased 
significantly and a precipitate was observed that corresponded 
to higher molecular weight aggregates as evidenced by SDS- 
PAGE under non-reductive conditions. Therefore, protein con- 
centration under folding for this fusion PI construction was 
fixed at 100/zg/ml. In order to look for an increase in folding 
efficiency at higher protein concentration, the effect of several 
additives in the buffer was evaluated. Chaotropic agents at low 
molar concentration (urea 0.5 M to 2 M, and guanidinium 
hydrochloride 0.5 M to 2 M), a modification of solvent polarity 
by addition of ethanol (2% to 20%) and the influence of zinc 
cations that could coordinate to the folding domain of proin- 
sulin (0.1 to 6 equivalents per mol of IL2-PI S-hexasulfonate), 
resulted in no substantial improvement or in a decrease in 
folding yield. 
3.4. Conditions for the enzymatic cleavage of lL2-Pl 
An essential aim of the present approach was the simultane- 
ous removal of both the N-terminal fused peptide and the 
C-peptide by trypsin digestion in presence of carboxypeptidase 
B. Due to the existence of two potential tryptic cleavage sites 
inside the insulin molecule (Arg 22 and Lys 29 in B-chain), it was 
necessary to search for highly selective reaction conditions. The 
explored experimental parameters included buffer pH (from 7.0 
to 10.5), trypsin/substrate ratio (from 1:50 to 1:1000), diges- 
tion time (from 10 min to 6 h) and temperature (4°C, 28°C and 
37°C). It was found that, while cleavage of the C-peptide pro- 
ceeded quantitatively in all the pH range investigated, the pH 
was critical on the removal of the N-terminal peptide and best 
results (over 90% as estimated by reversed phase HPLC) were 
attained at pH 9.0 and 9.5 (Fig. 4b). 
Modification of trypsin/substrate ratio resulted in severe 
changes in HPLC profiles. Best results, corresponding to min- 
imal internal cleavage inside B-chain and maximal removal of 
the N-terminal peptide, were obtained for a trypsin/substrate 
ratio in the range of 11400 to 1/600. On the other hand, while 
the C-peptide was totally removed after 10 min (pH 9.0, E/ 
S = 1/600, 37°C), removal of the N-terminal extension was 
completed only after prolonged reaction during 5 h (Fig. 4a). 
Under these conditions (pH 9.0, E/S = 1 : 600, 5 h, 37°C) des- 
octa-insulin (due to cleavage at Ar f  2) represented about 3%- 
8% as evaluated from several independent experiments. Varia- 
tion in this proportion could be related to differences in the 
specific activity of different batches of trypsin. Variations in 
temperature b tween 4°C and 37°C affected mainly the rate of 
the enzymatic digestion, and only slightly, the proportion be- 
tween human insulin and des-octa-insulin. 
Confirmation of the primary structure and disulfide bonds 
of the obtained recombinant insulin was made by a compara- 
tive HPLC mapping followed by FAB-MS analysis of the Glu- 
C endoproteinase digestion of our product and a human insulin 
standard. Identical HPLC maps were observed, and closely 
matched to those reported by Frank and coworkers [1]. 
The molecular ion mlz = 1378.0 (corresponding to the frag- 
ment A 18-21 + B 14-21) and the molecular ion m/z = 2967.9 (cor- 
responding to fragment A5-~7 + B 1-13) confirmed the correct 
arrangement of the interchain disulfide bonds. The internal 
disulfide bond in A-chain (Cys6-Cys 11) although not directly 
verified, was deduced to be correct based on the identity of 
HPLC Glu-C endoproteinase maps for the recombinant human 
insulin and the human insulin standard. 
4. Final comments 
As an attractive approach for processing insulin precursors 
in E. coli, it was conceived to fold the fusion protein, carrying 
a tryptic site at the end of the N-terminal extension, and then, 
to accomplish in a single step the removal of the C-peptide and 
176 L.R. Castellanos-Serra etal./FEBS Letters 378 (1996) 171-176 
the N-terminal extension. It was found that the chimeric LI2-PI 
protein could be correctly folded with yields about 80%. 
Nervertheless, while for PI S-hexasulfonate an effective process 
is reported at 2 mg/ml [1], here the protein concentration o  
folding had to be kept at 100-200/lg/ml. The way how this 
short peptide affected so drastically the folding behavior of the 
PI domain is not clear. The second objective of the present 
approach, the search for selective trypsination conditions to 
remove the stabilizer and the C-peptide, required a careful 
evaluation over an extensive set of experimental conditions. 
While a complete removal of the C-peptide took place always 
efficiently, conditions for an efficient cleavage of the N-termi- 
nal fused sequence that at the same time preserved B-chain 
integrity were difficult to achieve and, finally, were found by 
prolonging the reaction time up to 5 h while reducing apprecia- 
bly the enzyme/substrate ratio. 
The presented approach explored a route to the production 
of recombinant insulin in bacteria that avoids the use of cyan- 
ogen bromide. The search for other N-terminal fused sequences 
that may provide higher yields on folding at increased protein 
concentration is under study. 
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